Sanofi And Regeneron Expand Global Antibody Alliance To Co-Develop Four Long-Acting Immunology Antibodies - Sources

REGN20423 In Phase 1; Three More Antibodies Expected To Enter Studies In 2027 - Alliance May Include Sanofi s Lunsekimig Following Phase 3 Studies - Companies Settle Previous Collaboration-Related Litigation